ACA
MIST icon

Aptus Capital Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Aptus Capital Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$455K Buy
339,450
+59,200
+21% +$94.6K ﹤0.01% 815
2026
Q1 		$333K Buy
280,250
+17,050
+6% +$29.9K ﹤0.01% 841
2025
Q4 		$532K Buy
263,200
+53,000
+25% +$114K ﹤0.01% 714
2025
Q3 		$420K Buy
+210,200
New +$370K ﹤0.01% 744

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Aptus Capital Advisors's MIST Position: Q2 2026 in Review

Aptus Capital Advisors increased its Milestone Pharmaceuticals (MIST) stake by 21% in Q2 2026, buying an estimated $94.6K and bringing the position to 339,450 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #815.

Aptus Capital Advisors first reported a position in MIST in Q3 2025 and has held it in 4 quarters since. The position peaked at $532K in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Aptus Capital Advisors held 339,450 shares of Milestone Pharmaceuticals worth $455K as of Q2 2026.
  • Aptus Capital Advisors bought 59,200 Milestone Pharmaceuticals shares in Q2 2026, an estimated $94.6K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #815 holding.
  • Aptus Capital Advisors first reported a position in Milestone Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Aptus Capital Advisors's Milestone Pharmaceuticals position peaked at $532K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.